Transform our go-to-market model

More At-Risk Children in Developing Countries Are Protected From Pneumococcal Disease

For the third year in a row, given the strong, ongoing implementation of pneumococcal vaccine (PCV) country programs, Pfizer was able to lower the price of its multidose vial PCV13 for Gavi, The Vaccine Alliance, an international organization focused on improving access to new and under-used vaccines for children living in the world’s poorest countries. The reduction, from $2.95 to $2.90 per dose in Gavi-eligible countries, represents a nearly 14% reduction in price since the initial introduction of the vaccine into the Gavi Pneumococcal Advanced Market Commitment in 2010, reflecting a strong continued partnership to enable sustainable access to PCV13 in Gavi-eligible (and formerly Gavi-eligible) countries.

Pneumonia remains the single largest cause of death for children worldwide, and pneumococcal vaccination is an important weapon to fight it.1 Pfizer has provided nearly 500 million doses of PCV since partnering with Gavi in 2010.

Unleash the power of our people
Deliver first-in-class science
Transform our go-to-market model
Win the digital race in pharma
Lead the conversation